What Is Albrights Hereditary Osteodystrophy?

Albright’s hereditary osteodystrophy is a genetic condition that changes how the body responds to parathyroid hormone, a key regulator of calcium and phosphate. The result is a distinctive pattern of physical features, hormone resistance, and in some cases, problems with bone development and metabolism. It is not a disease of the parathyroid gland itself — the gland works, but the body’s cells respond to its signal poorly.

What Is Albrights Hereditary Osteodystrophy?

Albright’s hereditary osteodystrophy (AHO) is the physical and developmental syndrome caused by resistance to parathyroid hormone (PTH). It most often occurs as part of a broader condition called pseudohypoparathyroidism.

The name can be confusing. “Osteodystrophy” means abnormal bone development, but AHO involves more than bone. It includes short stature, shortened bones in the hands and feet, round face, and sometimes calcium and phosphate imbalances. It was first described by Dr. Fuller Albright in the 1940s, and the understanding of its genetics has expanded considerably since then.

The core problem is a signaling failure. PTH normally tells the kidneys and bones to adjust calcium and phosphate levels. In AHO, that message does not get through properly because of a defect in a protein called the Gs alpha subunit, which is needed for the hormone’s signal to work inside cells.

What Causes Albright’s Hereditary Osteodystrophy?

The cause is a change in the GNAS gene. This gene provides instructions for making the Gs alpha protein, which acts as a molecular switch inside cells. When PTH binds to its receptor, Gs alpha helps transmit the signal that raises calcium levels and lowers phosphate levels in the blood.

When GNAS is altered, that switch does not function normally. The parathyroid glands may produce plenty of PTH, but the kidneys and bones do not respond as they should. This is why the condition is sometimes called “pseudohypoparathyroidism” — the hormone is present, but the body acts as if it is not.

The genetics are more complex than a simple dominant or recessive pattern. GNAS is an imprinted gene, meaning it behaves differently depending on whether it is inherited from the mother or the father. This imprinting explains why the same genetic change can produce different features in different people, even within the same family.

What Are the Symptoms and Physical Features?

The physical features of AHO are usually noticeable in childhood, though the timing and severity vary widely. Not everyone has every feature.

Common physical signs include:

• Short stature, often below the normal growth curve
• Shortened bones in the hands and feet, especially the fourth and fifth fingers and toes (brachydactyly)
• A round, full face
• Short, thick neck
• Dental problems, including delayed eruption or enamel defects
• Areas of bone under the skin (subcutaneous ossifications)
• Mild intellectual disability or learning differences in some cases

The hormone-related symptoms depend on which hormones are affected. When PTH resistance is significant, low calcium and high phosphate can cause muscle cramps, tingling in the hands and feet, seizures, or cataracts over time. Some people also have resistance to thyroid-stimulating hormone, which can lead to thyroid problems.

It is important to understand that the physical features and the hormone problems do not always go together. Some people have the characteristic appearance without major calcium issues. Others have significant hormone resistance with fewer outward signs.

How Is It Diagnosed?

Diagnosis usually involves a combination of physical examination, blood tests, and sometimes genetic testing.

Blood tests typically show low calcium, high phosphate, and elevated PTH levels. These findings point to PTH resistance rather than a problem with the parathyroid gland itself. The parathyroid glands are working — often working harder than normal — but the body is not responding.

Genetic testing can confirm a GNAS mutation, but it is not always necessary for diagnosis. The combination of physical features and hormone abnormalities is often enough to make the diagnosis. Genetic testing may be helpful for family planning or when the picture is unclear.

Imaging may show shortened bones or other skeletal changes. A doctor may also check for other hormone problems, such as thyroid or growth hormone issues, since these can occur alongside PTH resistance.

How Is It Treated?

There is no cure for AHO, and treatment focuses on managing symptoms and preventing complications. The approach depends on which features are present and how severe they are.

When calcium and phosphate levels are abnormal, treatment often includes calcium supplements and active vitamin D (calcitriol). This is not the same as ordinary vitamin D. Active vitamin D helps the body absorb calcium even when PTH signaling is impaired. Some clinicians also recommend phosphate binders to lower phosphate levels.

The goal of treatment is to keep calcium and phosphate in a range that prevents symptoms and long-term problems, without causing other issues. This requires regular monitoring. Too much calcium can cause kidney problems, and too little can cause seizures or other serious symptoms.

Other treatments may address specific problems:

• Growth hormone therapy may be considered for short stature in some children, though evidence for its effectiveness in AHO specifically is limited
• Dental care and orthodontics for dental issues
• Physical therapy for mobility or bone problems
• Educational support for learning differences
• Treatment for thyroid or other hormone problems if present

No clinical guidelines currently exist for treating every aspect of AHO, and management is often individualized. What works for one person may not be appropriate for another.

What Is the Outlook for People With AHO?

The outlook varies widely. Some people have mild features and few health problems. Others have more significant hormone issues that require ongoing management.

With appropriate monitoring and treatment, many people with AHO live full lives. The key is catching and managing calcium and phosphate problems early, since untreated imbalances can lead to seizures, cataracts, or other complications over time.

Short stature and the physical features of AHO do not improve with treatment. They are part of the condition. But the hormone-related problems can often be managed effectively with medication and regular follow-up.

It is also worth noting that AHO is a lifelong condition. It does not go away, and it requires ongoing attention. But it is not typically life-threatening when managed well.

How Does AHO Differ From Other Calcium Disorders?

AHO is one of several conditions that affect calcium and phosphate balance, and it is easy to confuse with others. The key difference is the underlying mechanism.

In hypoparathyroidism, the parathyroid glands do not produce enough PTH. In AHO, the glands produce PTH — often more than normal — but the body does not respond to it. This distinction matters because the treatments are different.

In vitamin D deficiency, low calcium is caused by insufficient vitamin D, which is needed for calcium absorption. In AHO, vitamin D may be normal, but the body still cannot regulate calcium properly because of the PTH signaling problem.

Some people with AHO also have resistance to other hormones, such as thyroid-stimulating hormone. This is part of the same underlying Gs alpha defect. It is not a separate disease but another manifestation of the same genetic change.